CC Chemours Co

NYSE Chemicals & Allied Products DE CIK: 0001627223
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

Chemours is in severe financial distress with persistent operating losses, negative free cash flow of -$93M, and a critically unsustainable debt-to-equity ratio of 19.07x that prevents interest coverage. The company cannot service its $4.1B debt burden from operations and faces acute solvency risk without significant operational turnaround.

Strengths

  • + Maintains $563M cash reserves providing near-term liquidity buffer
  • + Gross margin of 15.4% provides runway for operational improvements
  • + Current ratio of 1.82x indicates adequate short-term working capital

Risks

  • ! Negative free cash flow of -$93M annually means unsustainable cash burn at current pace
  • ! Debt-to-equity of 19.07x with negative interest coverage (-0.3x) indicates inability to service debt from operations
  • ! Operating losses destroying shareholder value (ROE -13.5%, ROA -0.4%)
  • ! Flat revenue growth of +0.4% YoY provides no organic growth to support debt reduction
  • ! Quick ratio of 0.87x below 1.0 signals potential liquidity stress beyond cash reserves

Key Metrics to Watch

Financial Metrics

Revenue
1.4B
Net Income
-29.0M
EPS (Diluted)
$-0.19
Free Cash Flow
-93.0M
Total Assets
7.3B
Cash
563.0M

Profitability Ratios

Gross Margin 15.4%
Operating Margin -1.6%
Net Margin -2.1%
ROE -13.5%
ROA -0.4%
FCF Margin -6.7%

Balance Sheet & Liquidity

Current Ratio
1.82x
Quick Ratio
0.87x
Debt/Equity
19.07x
Debt/Assets
97.0%
Interest Coverage
-0.32x
Long-term Debt
4.1B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-07T08:21:02.177201 | Data as of: 2026-03-31 | Powered by Claude AI